Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication

Virology Journal

Lianfeng Zhang²  Chuan Qin²  Chunmei Ma²  Yanfeng Xu²  Yajun Yang¹  Jiangning Liu¹ 

[1] Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health; Institute of Laboratory Animal Science, CAMS & Comparative Medicine Centre, PUMC, Chao Yang Strict, Pan Jia Yuan Nan Li No.5, Beijing 100021, China;Key Laboratory of Human Diseases Animal Models, State administration of Traditional Chinese Medicine; Institute of Laboratory Animal Science, CAMS & Comparative Medicine Centre, PUMC, Chao Yang Strict, Pan Jia Yuan Nan Li No.5, Beijing 100021, China

关键词: Drug;    Mouse model;    Lycorine;    Human enterovirus 71;   

Others  :  1155811
DOI  :  10.1186/1743-422X-8-483

 received in 2011-06-29, accepted in 2011-10-27,  发布年份 2011

【 摘 要 】

Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications. No vaccines or drugs are clinical available to control EV71 epidemics. In present study, we show that treatment with lycorine reduced the viral cytopathic effect (CPE) on rhabdomyosarcoma (RD) cells by inhibiting virus replication. Analysis of this inhibitory effect of lycorine on viral proteins synthesis suggests that lycorine blocks the elongation of the viral polyprotein during translation. Lycorine treatment of mice challenged with a lethal dose of EV71 resulted in reduction of mortality, clinical scores and pathological changes in the muscles of mice, which were achieved through inhibition of viral replication. When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis. Lycorine may be a potential drug candidate for the clinical treatment of EV71-infected patients.

【 授权许可】

   
2011 Liu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 3.

Figure 7.

【 参考文献 】

• [1]Schmidt NJ, Lennette EH, Ho HH: An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974, 129:304-309.
• [2]Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT: Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009, 38:106-112.
• [3]Chang LY: Enterovirus 71 in Taiwan. Pediatr Neonatol 2008, 49:103-112.
• [4]Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al.: Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000, 31:678-683.
• [5]Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, Lin TY: Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007, 356:1226-1234.
• [6]Chang LY, Lee CY, Kao CL, Fang TY, Lu CY, Lee PI, Huang LM: Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1980-1981. J Formos Med Assoc 2007, 106:173-176.
• [7]Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY: Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999, 354:1682-1686.
• [8]Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, Earl P, Bendig J, Tong CY: Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 2008, 46:3192-3200.
• [9]Enterovirus 71: epidemiology and diagnostics Zh Mikrobiol Epidemiol Immunobiol 2009, 110-116.
• [10]Ma E, Chan KC, Cheng P, Wong C, Chuang SK: The enterovirus 71 epidemic in 2008--public health implications for Hong Kong. Int J Infect Dis 14:e775-780.
• [11]Chang LY, Chang IS, Lu CY, Chiang BL, Lee CY, Chen PJ, Wang JT, Ho HN, Chen DS, Huang LM: Epidemiologic features of Kawasaki disease in Taiwan, 1996-2002. Pediatrics 2004, 114:e678-682.
• [12]Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, Ishiko H, Suzuki H: Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J 2006, 25:691-694.
• [13]Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, et al.: An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009, 44:262-267.
• [14]Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM: Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res 2005, 67:31-37.
• [15]Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, Yu CK, Chen SH: Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 2008, 197:854-857.
• [16]Sim AC, Luhur A, Tan TM, Chow VT, Poh CL: RNA interference against enterovirus 71 infection. Virology 2005, 341:72-79.
• [17]Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, Su IJ, Wang JR, Yeh TM, Chen SH, Yu CK: Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 2005, 86:3263-3269.
• [18]Jaspersen-Schib R: Toxic amaryllidaceas. Pharm Acta Helv 1970, 45:424-433.
• [19]Lamoral-Theys D, Decaestecker C, Mathieu V, Dubois J, Kornienko A, Kiss R, Evidente A, Pottier L: Lycorine and its derivatives for anticancer drug design. Mini Rev Med Chem 2010, 10:41-50.
• [20]Cedron JC, Gutierrez D, Flores N, Ravelo AG, Estevez-Braun A: Synthesis and antiplasmodial activity of lycorine derivatives. Bioorg Med Chem 2010, 18:4694-4701.
• [21]Mikami M, Kitahara M, Kitano M, Ariki Y, Mimaki Y, Sashida Y, Yamazaki M, Yui S: Suppressive activity of lycoricidinol (narciclasine) against cytotoxicity of neutrophil-derived calprotectin, and its suppressive effect on rat adjuvant arthritis model. Biol Pharm Bull 1999, 22:674-678.
• [22]Kretzing S, Abraham G, Seiwert B, Ungemach FR, Krugel U, Regenthal R: Dose-dependent emetic effects of the Amaryllidaceous alkaloid lycorine in beagle dogs. Toxicon 2011, 57:117-124.
• [23]Ieven M, van den Berghe DA, Vlietinck AJ: Plant antiviral agents. IV. Influence of lycorine on growth pattern of three animal viruses. Planta Med 1983, 49:109-114.
• [24]Szlavik L, Gyuris A, Minarovits J, Forgo P, Molnar J, Hohmann J: Alkaloids from Leucojum vernum and antiretroviral activity of Amaryllidaceae alkaloids. Planta Med 2004, 70:871-873.
• [25]Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, et al.: Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 2005, 67:18-23.
• [26]Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, et al.: Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28:7444-7451.
• [27]Reed LJM, Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
• [28]Massignan T, Stewart RS, Biasini E, Solomon IH, Bonetto V, Chiesa R, Harris DA: A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein. J Biol Chem 2010, 285:7752-7765.
• [29]Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, Hao Y, Gao XZ, Liu XL, Xu YF, Zhang LF, Qin C: The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 2010, 7:47. BioMed Central Full Text
• [30]Jimenez ALS, Vazquez D: Yeast ribosomal sensitivity and resistance to the AMARYLLIDA ALKALOIDS . FEBS Letters 1975, 60:66-70.
• [31]Jimenez A, Santos A, Alonso G, Vazquez D: Inhibitors of protein synthesis in eukarytic cells. Comparative effects of some amaryllidaceae alkaloids. Biochim Biophys Acta 1976, 425:342-348.
• [32]Kukhanova M, Victorova L, Krayevsky A: Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS Lett 1983, 160:129-133.
• [33]Rombaut B, Vrijsen R, Delgadillo R, Vanden Berghe D, Boeye A: Characterization and assembly of poliovirus-related 45 S particles. Virology 1985, 146:111-119.
• [34]Brown BA, Pallansch MA: Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995, 39:195-205.
• [35]Jiang H, Weng L, Zhang N, Arita M, Li R, Chen L, Toyoda T: Biochemical characterization of enterovirus 71 3D RNA polymerase. Biochim Biophys Acta 2011, 1809:211-219.
• [36]Mrvos R, Krenzelok EP, Jacobsen TD: Toxidromes associated with the most common plant ingestions. Vet Hum Toxicol 2001, 43:366-369.